

April 4, 2022

David Wright
Director Quality, Safety and Oversight Group
Centers for Medicare and Medicaid Services
7500 Security Blvd Mailstop C2-21-16
Baltimore, MD 21244

Regina Van Brakle
Acting Division Director DCLIQ
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244

Dear Mr. Wright and Ms Van Brakle:

Subject: Request for information (CMS-03326-NC) related to 42 CFR

Numerous advances have taken place over the last 30 years in the setting of clinical histocompatibility testing and the practice of solid organ transplantation. A majority of donor/recipient compatibility assessments no longer require a pre-transplant physical crossmatch (ie; testing recipient sera against donor lymphocytes). Rather, **due to advances in HLA antibody testing technologies, immunologic compatibility between a given donor and recipient can be assessed “virtually” using HLA antibody profiles and donor HLA genotyping data, without the need for a physical crossmatch.** In November of 2014, CLIAC recommended that CMS “...explore; regulatory changes or guidance that would allow virtual crossmatching to replace physical crossmatching as a pre-requisite for organ transplantation.”¹

On the 9th of January 2018 the Centers for Medicare and Medicaid Services (CMS) issued a Request for information (RFI) on several aspects of 42 CFR §493. Specifically, CMS sought input on *Revisions to Personnel Regulations, Proficiency Testing Referral, Histocompatibility Regulations and Fee Regulations* under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) (Federal Register Docket CMS-3326–NC). **We, the undersigned organizations and individuals, are contacting CMS to request a revision of a rule addressed in this RFI; specifically, section C, Histocompatibility; sub-section 1, Crossmatching.** This particular section requested comments on the proposed rule related to 42 CFR §493.1278(e-f) and the use of a “virtual crossmatch” in lieu of a physical crossmatch.

The Clinical Laboratory Improvement Act of 1988 (CLIA) has not undergone any updates to histocompatibility-specific regulations since 1992 and therefore certain requirements lag far behind current clinical capabilities. Most notably is 423 CFR §493.1278(f)(2) and its requirement that laboratories;

“For renal allo-transplantation and combined organ and tissue transplants in which a kidney is to be transplanted, have available results of final crossmatches before the kidney is transplanted.”

CMS specifically stated in this RFI that “although not specified in the regulation, the crossmatching procedures in use in 1992 were physical crossmatches”, as well as that regulatory changes may be necessary to allow virtual crossmatching to replace physical crossmatching prior to organ transplantation.

For the laboratory, the American Society for Histocompatibility and Immunogenetics (ASHI) has recently developed **regulatory guidelines for “Virtual Crossmatching” that have been approved by CMS** (ASHI- Standards for Accredited Laboratories, 2020 Revised Standards. Approved by CMS: February 16, 2021; available at www.ashi-hla.org). For the transplant center, newer therapeutic options to mitigate recipient/donor HLA incompatibilities at the time of transplantation have meant that a positive physical crossmatch is no longer an absolute contraindication to transplantation. Importantly for some patients a

false-positive physical crossmatch (absence of donor-specific HLA antibodies) can mistakenly prevent safe transplantation and increase the risk of a candidate dying on the transplant waiting list, as false positive reactions can occur up to 20% of the time². Thus, the final decision to transplant a candidate is based on the immunological assessment provided by the histocompatibility laboratory as well as the specific clinical practices of the individual transplant program as they are applied to each individual patient based on the patient's medical urgency and level of immunologic risk.

To date, the delay in a decision by CMS on this specific issue has created significant concerns within the transplant community. Many centers have adopted virtual crossmatching as a "standard of practice" to improve patient outcomes, while others are hesitant due to the regulatory ambiguity. However, there are numerous scientific publications, worldwide, providing evidence for the clinical utility and safety of this practice²⁻¹⁹. In fact, many organizations such as ASHI, UNOS, CAP, ACLA (Am Clinical Laboratory Assoc.) and AHA (Am. Hospital Assoc.) submitted letters in response to the RFI supporting the adoption of the virtual crossmatch.

Of importance, recent changes in deceased-donor kidney allocation established wider regional and national sharing of kidney allografts, as the removal of donor service areas (DSAs) as a unit of allocation was required by the Department of Health and Human Services (HHS). Renal allograft distribution over broader distances has increased the need for virtual crossmatching to reduce allograft cold-time ischemic injury and facilitate equitable allocation to immunologically sensitized patients. This need may increase with the proposed "Continuous Distribution" model for organ allocation²⁰. Requiring a physical crossmatch specifically disadvantages immunologically sensitized patients who depend on nationally shared allografts and 42 USC §274(2)(A)(ii) requires the national organ allocation system to consider "individuals whose immune system makes it difficult for them to receive organs". We cannot in good faith recommend continuing a practice that is often not needed due to technological advances, and that enforces a systemic inequity towards biologically disadvantaged patients.

Due to advances in clinical capabilities, we feel that it is necessary to codify this aspect of clinical histocompatibility laboratory practice. The virtual crossmatch needs to be deemed equivalent to a physical crossmatch for final immunological evaluation, thereby permitting transplant programs and histocompatibility laboratories to use a safe and established practice without reservation or limitation. **We request a meeting at your earliest convenience to address any questions that you may have regarding our concerns about the current federal regulation and request for an expedient update.**

Sincerely,



Dr. Annette M. Jackson PhD, F(ACHI)
ASHI President

Associate Professor, Departments of Surgery & Immunology
Co-Director, Clinical Transplantation Immunology Laboratory
Duke University Medical Center, Durham, NC



Dr. Robert Bray PHD, D(ABHI), HCLD/CC(ABB)

Chair, CLIAC Virtual Crossmatch Workgroup

Professor, of Pathology

Co-Directory, Histocompatibility and Molecular Immunogenetics Laboratory

Emory University, Atlanta, GA



Dr. Pete Lalli PhD, F(ACHI)

Chair, UNOS Histocompatibility Committee

Director, Histocompatibility and Flow Cytometry Laboratory

Carolinas Pathology Group

Atrium Health, Charlotte, NC



Dr. Matthew Cooper, MD, FACS

President, United Network for Organ Sharing

Director, Kidney and Pancreas Transplantation

Medstar Georgetown Transplant Institute

Professor of Surgery

Georgetown University School of Medicine



Emily E. Volk, MD, FCAP

President, College of American Pathologists

Associate Professor, Pathology and Laboratory Medicine

University of Louisville School of Medicine



John S. Gill, MD, MS

President, American Society of Transplantation

Professor of Medicine, Nephrology Division

University of British Columbia



Jan Finn RN, MSN
President, Association of Organ Procurement Organizations
President & CEO, Midwest Transplant Network



A. Osama Gaber, MD, FACS
President, American Society of Transplant Surgeons
Chair, Department of Surgery
Professor of Surgery, Weill Cornell Medicine, HMAI
John F., Jr. and Carolyn Bookout Presidential Distinguished Chair
Founding Director, J.C. Walter Jr. Transplant Center

cc

CDC: Reynolds M. Salerno, Leslie Dauphin and Nancy Anderson

CMS: Sarah.Bennett

Office of the Assistant Secretary for Health (OASH): Rachel L. Levine

References:

1. Clinical Laboratory Improvement Advisory Committee Summary Report. November 5-6, 2014 Atlanta, Georgia. https://www.cdc.gov/cliac/docs/summary/cliac1114_summary.pdf
2. Sullivan HC, et al; Hum Immunol. Utility of the physical crossmatch for living donor evaluations in the age of the virtual crossmatch. Human Immunol 79 (2018) 711–715.
3. D. Biemann, G. Honger, D. Lutz, M.J. Mihatsch, J. Steiger, S. Schaub, Pretransplant risk assessment in renal allograft recipients using virtual crossmatching, Am. J. Transplant. 7 (2007) 626–632.
4. S. Zangwill, T. Ellis, G. Stendahl, A. Zahn, S. Berger, J. Tweddell, Practical application of the virtual crossmatch, Pediatr. Transplant. 11 (2007) 650–654.
5. A.W. Bingaman, C.L. Murphey, J. Palma-Vargas, F. Wright, A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation, Transplantation 86 (2008) 1864–1868.
6. A.A. Zachary, J.T. Sholander, J.A. Houp, M.S. Leffell, Using real data for a virtual crossmatch. Human Immunol 70 (2009) 574–579.

7. A. Nikaein, W. Cherikh, K. Nelson, T. Baker, S. Leffell, L. Bow, D. Crowe, K. Connick, M.A. Head, M. Kamoun, P. Kimball, E. Klohe, H. Noreen, L. Rebellato, T. Sell, K. Sullivan, G. Land, Organ procurement and transplantation network/united network for organ sharing histocompatibility committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients, *Transplantation* 87 (2009) 557–562.
8. C.J. Taylor, V. Kosmoliaptsis, L.D. Sharples, D. Prezzi, C.H. Morgan, T. Key, A.N. Chaudhry, I. Amin, M.R. Clatworthy, A.J. Butler, C.J. Watson, J.A. Bradley, Ten-year experience of selective omission of the pretransplant crossmatch test in deceased donor kidney transplantation, *Transplantation* 89 (2010) 185–193.
9. G.P. Morris, D.L. Phelan, M.D. Jendrisak, T. Mohanakumar, Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation, *Hum. Immunol.* 71 (2010) 268–273.
10. P. Amico, P. Hirt-Minkowski, G. Honger, L. Gurke, M.J. Mihatsch, J. Steiger, H. Hopfer, S. Schaub, Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations, *Transpl. Int.* 24 (2011) 560–569.
11. C.M. Worsley, E.S. Mayne, M.S. Suchard, Luminex-based virtual crossmatching for renal transplantation in South Africa, *S. Afr. Med. J.* 102 (2011) 40–43.
12. P. Ferrari, S. Fidler, J. Wright, C. Woodroffe, P. Slater, A. Van Althuis-Jones, R. Holdsworth, F.T. Christiansen, Virtual crossmatch approach to maximize matching in paired kidney donation, *Am. J. Transplant.* 11 (2011) 272–278.
13. G.A. Bohmig, S. Fidler, F.T. Christiansen, G. Fischer, P. Ferrari, Transnational validation of the Australian algorithm for virtual crossmatch allocation in kidney paired donation, *Hum. Immunol.* 74 (2013) 500–505.
14. C.P. Johnson, J.J. Schiller, Y.R. Zhu, S. Hariharan, A.M. Roza, D.C. Cronin, B.D. Shames, T.M. Ellis, Renal transplantation with final allocation based on the virtual crossmatch, *Am. J. Transplant.* 16 (2016) 1503–1515.
15. J. Lunz, L. Hinsdale, C. King, R. Pastush, M. Buenvenida, M. Harmon, The coordination of allocation: logistics of kidney organ allocation to highly sensitized patients, *Hum. Immunol.* 78 (2017) 16–18.
16. J.P. Perasaari, T. Jaatinen, J. Merenmies, Donor-specific HLA antibodies in predicting crossmatch outcome: comparison of three different laboratory techniques, *Transplant Immunol* 46 (2018) 23-28.
17. D. Turner, R. Battle, A. Akbarzad-Yousefi, A.M. Little, The omission of the wet pre-transplant crossmatch in renal transplant centres in Scotland, *HLA* 94(2019) 3–10.
18. A.B. Morris, H.C. Sullivan, S.M. Krummey, H.M. Gebel, R.A. Bray, Out with the old, in with the new: virtual versus physical crossmatching in the modern era. *HLA* 94 (2019) 471–481.
19. G.R. Roll, A.B. Webber, D.H. Gae, et al., A virtual crossmatch based strategy facilitates sharing of deceased donor kidneys for highly sensitized recipients. *Transplantation* 104 (2020) 1239–1245.
20. Organ Procurement and Transplantation Network: Continuous distribution
<https://optn.transplant.hrsa.gov/policies-bylaws/a-closer-look/continuous-distribution>